1
|
Serratrice C, Stirnemann J, Berrahal A, Belmatoug N, Camou F, Caillaud C, Billette de Villemeur T, Dalbies F, Cador B, Froissart R, Masseau A, Brassier A, Hivert B, Swiader L, Bertchansky I, de Moreuil C, Chabrol B, Durieu I, Leguy Seguin V, Astudillo L, Humbert S, Pichard S, Marcel C, Hau Rainsard I, Bengherbia M, Yousfi K, Berger MG. A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease. J Clin Med 2020; 9:jcm9082343. [PMID: 32708003 PMCID: PMC7464688 DOI: 10.3390/jcm9082343] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 07/14/2020] [Accepted: 07/20/2020] [Indexed: 01/16/2023] Open
Abstract
Patients with type 1 Gaucher disease (GD1) present thrombocytopenia, anemia, organomegaly, and bone complications. Most experts consider that the less aggressive forms do not require specific treatment. However, little is known about the disease course of these forms. The objective of this cross-sectional retrospective study was to compare the clinical, radiological, and laboratory characteristics of patients with less severe GD1 at diagnosis and at the last evaluation to identify features that might lead to potential complications. Non-splenectomized and never-treated patients (19 women and 17 men) were identified in the French Gaucher Disease Registry (FGDR). Their median age was 36.6 years (2.4–75.1), and their median follow-up was 7.8 years (0.4–32.4). Moreover, 38.7% were heterozygous for the GBA1 N370S variant, and 22.6% for the GBA1 L444P variant. From diagnosis to the last evaluation, GD1 did not worsen in 75% of these patients. Some parameters improved (fatigue and hemoglobin concentration), whereas platelet count and chitotriosidase level remained stable. In one patient (2.7%), Lewy body dementia was diagnosed at 46 years of age. Bone lesion onset was late and usually a single event in most patients. This analysis highlights the genotypic heterogeneity of this subgroup, in which disease could remain stable and even improve spontaneously. It also draws attention to the possible risk of Lewy body disease and late onset of bone complications, even if isolated, to be confirmed in larger series and with longer follow-up.
Collapse
Affiliation(s)
- Christine Serratrice
- Department of Internal Medicine for the Aged, Geneva University Hospitals, 1226 Thonex- Geneva, Switzerland
- Correspondence: ; Tel.: +4179-873-1474
| | - Jérôme Stirnemann
- Department of Internal Medicine, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland;
| | - Amina Berrahal
- University Hospital of Clermont Ferrand, Hematology Biology Department, 63000 Clermont-Ferrand, France; (A.B.); (M.G.B.)
| | - Nadia Belmatoug
- Department of Internal Medicine, Centre de Référence des Maladies Lysosomales, AP-HP.Nord, Site Beaujon, Paris University, 92110 Clichy, France; (N.B.); (C.M.); (M.B.); (K.Y.)
| | - Fabrice Camou
- Intensive Care Unit, Hôpital Saint-André, CHU Bordeaux, 33000 Bordeaux, France;
| | - Catherine Caillaud
- Biochemistry, Metabolomics, and Proteomics Department, Necker Enfants Malades University Hospital, AP-HP. Center-Paris University, 75015 Paris, France;
| | | | - Florence Dalbies
- Institute of Cancerology and Hematology, CHRU Morvan, 29200 Brest, France;
| | - Bérengère Cador
- Department of Internal Medicine, CHU Pontchaillou, 35000 Rennes, France;
| | - Roseline Froissart
- Biochemical and Molecular Biology Department, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500 Bron, France;
| | - Agathe Masseau
- Department of Internal Medicine, CHU Hôtel Dieu, 44093 Nantes, France;
| | - Anaïs Brassier
- Reference Centre for Hereditary Metabolic Diseases, Hôpital Necker-Enfants Malades, AP-HP, IHU Institut Imagine, 75015 Paris, France;
| | - Bénédicte Hivert
- Department of Clinical Hematology, Hôpital Saint Vincent de Paul, Groupement des Hôpitaux de l’Institut Catholique de Lille, 59800 Lille, France;
| | - Laure Swiader
- Department of Internal Medicine, CHU Timone, 13005 Marseille, France;
| | - Ivan Bertchansky
- Department of Internal Medicine, Saint-Eloi Hospital, CHU Montpellier, 34000 Montpellier, France;
| | - Claire de Moreuil
- Department of Internal Medicine, Hôpital de la Cavale Blanche, CHRU de Brest, 29200 Brest, France;
| | - Brigitte Chabrol
- Department of Pediatric Neurology, CHU Timone, 13005 Marseille, France;
| | - Isabelle Durieu
- Department of Internal Medicine, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 69495 Pierre-Bénite, France;
| | - Vanessa Leguy Seguin
- Department of Internal Medicine and Clinical Immunology, CHU F. Mitterrand, 21000 Dijon, France;
| | | | - Sébastien Humbert
- Department of Internal Medicine, Besancon University Hospital, 25000 Besancon, France;
| | - Samia Pichard
- Service of Metabolic Diseases, Hôpital Robert Debré, 75019 Paris, France;
| | - Catherine Marcel
- Department of Internal Medicine, Centre de Référence des Maladies Lysosomales, AP-HP.Nord, Site Beaujon, Paris University, 92110 Clichy, France; (N.B.); (C.M.); (M.B.); (K.Y.)
| | | | - Monia Bengherbia
- Department of Internal Medicine, Centre de Référence des Maladies Lysosomales, AP-HP.Nord, Site Beaujon, Paris University, 92110 Clichy, France; (N.B.); (C.M.); (M.B.); (K.Y.)
| | - Karima Yousfi
- Department of Internal Medicine, Centre de Référence des Maladies Lysosomales, AP-HP.Nord, Site Beaujon, Paris University, 92110 Clichy, France; (N.B.); (C.M.); (M.B.); (K.Y.)
| | - Marc G. Berger
- University Hospital of Clermont Ferrand, Hematology Biology Department, 63000 Clermont-Ferrand, France; (A.B.); (M.G.B.)
- University Clermont Auvergne, EA 7453 CHELTER, 63000 Clermont-Ferrand, France
| |
Collapse
|
2
|
Villard O, Morquin D, Molinari N, Raingeard I, Nagot N, Cristol JP, Jung B, Roubille C, Foulongne V, Fesler P, Lamure S, Taourel P, Konate A, Maria ATJ, Makinson A, Bertchansky I, Larcher R, Klouche K, Le Moing V, Renard E, Guilpain P. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. J Clin Med 2020; 9:jcm9072315. [PMID: 32708205 PMCID: PMC7408691 DOI: 10.3390/jcm9072315] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 07/15/2020] [Accepted: 07/17/2020] [Indexed: 01/08/2023] Open
Abstract
Background. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. Methods. Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. Disease severity was assessed using a seven-category ordinal scale. Primary outcome of interest was the severity of patients’ clinical courses. Results. Forty-four patients were included. At inclusion, 12 patients had mild clinical status, 25 moderate clinical status and 7 severe clinical status. In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (p < 0.01 and p = 0.03, respectively). In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Conclusions. Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19. Our findings may open new perspectives in the understanding of the possible role of RAAS for Covid-19 outcome.
Collapse
Affiliation(s)
- Orianne Villard
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Endocrinology, Diabetes, Nutrition, and INSERM 1411 Clinical Investigation Centre, Montpellier University Hospital, INSERM, 34000 Montpellier, France;
- Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, 34000 Montpellier, France
| | - David Morquin
- Department of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, France;
| | - Nicolas Molinari
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- IMAG, CNRS, University of Montpellier, Montpellier University Hospital, 34000 Montpellier, France
| | - Isabelle Raingeard
- Department of Endocrinology, Diabetes, Nutrition, and INSERM 1411 Clinical Investigation Centre, Montpellier University Hospital, INSERM, 34000 Montpellier, France;
| | - Nicolas Nagot
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- IMAG, CNRS, University of Montpellier, Montpellier University Hospital, 34000 Montpellier, France
| | - Jean-Paul Cristol
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Laboratory of Biochemistry, Montpellier University Hospital, 34000 Montpellier, France
| | - Boris Jung
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Intensive Care Medicine, Montpellier University Hospital, 34000 Montpellier, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 34000 Montpellier, France
| | - Camille Roubille
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 34000 Montpellier, France
| | - Vincent Foulongne
- Laboratory of Virology, Montpellier University Hospital, 34000 Montpellier, France;
| | - Pierre Fesler
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 34000 Montpellier, France
| | - Sylvain Lamure
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, France;
| | - Patrice Taourel
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Radiology, Montpellier University Hospital, 34000 Montpellier, France
| | - Amadou Konate
- Department of Internal Medicine—Multi-Organ Diseases, Local Referral Center for Auto-Immune Diseases, Montpellier University Hospital, 34000 Montpellier, France; (A.K.); (I.B.)
- Department of Internal Medicine—‘DIAGORA Unit’, Montpellier University Hospital, 34000 Montpellier, France
| | - Alexandre Thibault Jacques Maria
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Internal Medicine—Multi-Organ Diseases, Local Referral Center for Auto-Immune Diseases, Montpellier University Hospital, 34000 Montpellier, France; (A.K.); (I.B.)
- IRMB, INSERM U1183, Montpellier University Hospital, 34000 Montpellier, France
| | - Alain Makinson
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, France;
| | - Ivan Bertchansky
- Department of Internal Medicine—Multi-Organ Diseases, Local Referral Center for Auto-Immune Diseases, Montpellier University Hospital, 34000 Montpellier, France; (A.K.); (I.B.)
- Department of Internal Medicine—‘DIAGORA Unit’, Montpellier University Hospital, 34000 Montpellier, France
| | - Romaric Larcher
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Intensive Care Medicine, Montpellier University Hospital, 34000 Montpellier, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 34000 Montpellier, France
| | - Kada Klouche
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Intensive Care Medicine, Montpellier University Hospital, 34000 Montpellier, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, 34000 Montpellier, France
| | - Vincent Le Moing
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, France;
| | - Eric Renard
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Endocrinology, Diabetes, Nutrition, and INSERM 1411 Clinical Investigation Centre, Montpellier University Hospital, INSERM, 34000 Montpellier, France;
- Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, 34000 Montpellier, France
| | - Philippe Guilpain
- Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France; (O.V.); (N.M.); (N.N.); (J.-P.C.); (B.J.); (C.R.); (P.F.); (S.L.); (P.T.); (A.T.J.M.); (A.M.); (R.L.); (K.K.); (V.L.M.); (E.R.)
- Department of Internal Medicine—Multi-Organ Diseases, Local Referral Center for Auto-Immune Diseases, Montpellier University Hospital, 34000 Montpellier, France; (A.K.); (I.B.)
- IRMB, INSERM U1183, Montpellier University Hospital, 34000 Montpellier, France
- Correspondence: ; Tel.: +33-4-67-33-73-32; Fax: +33-4-67-33-72-91
| |
Collapse
|
3
|
Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1. Clin Pharmacokinet 2020; 58:469-482. [PMID: 30128966 DOI: 10.1007/s40262-018-0708-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND AND OBJECTIVES Intravenous imiglucerase enzyme replacement therapy for Gaucher disease type 1 administered every 2 weeks is at variance with the imiglucerase plasma half-life of a few minutes. We hypothesized that studying the pharmacokinetics of imiglucerase in blood Gaucher disease type 1 monocytes would be more relevant for understanding enzyme replacement therapy responses. METHODS Glucocerebrosidase intra-monocyte activity was studied by flow cytometry. The pharmacokinetics of imiglucerase was analyzed using a population-pharmacokinetic model from a cohort of 31 patients with Gaucher disease type 1 who either started or were receiving long-term treatment with imiglucerase. RESULTS A pharmacokinetic analysis of imiglucerase showed a two-compartment model with a high peak followed by a two-phase exponential decay (fast phase half-life: 0.36 days; slow phase half-life: 9.7 days) leading to a median 1.4-fold increase in glucocerebrosidase intra-monocyte activity from the pre-treatment activity (p = 0.04). In patients receiving long-term treatment, for whom the imiglucerase dose per infusion was chosen on the basis of disease aggressiveness/response, imiglucerase clearance correlated with the administered dose. However, the residual glucocerebrosidase intra-monocyte activity value was dose independent, suggesting that the maintenance of imiglucerase residual activity is patient specific. Endogenous pre-treatment glucocerebrosidase intra-monocyte activity was the most informative single parameter for distinguishing patients without (n = 10) and with a clinical indication (n = 17) for starting enzyme replacement therapy (area under the receiver operating characteristic curve: 0.912; 95% confidence interval 0.8-1; p < 0.001), as confirmed also by a factorial analysis of mixed data. CONCLUSION This study provides novel pharmacokinetic data that support current imiglucerase administration regimens and suggests the existence of a glucocerebrosidase activity threshold related to Gaucher disease type 1 aggressiveness. These findings can potentially improve Gaucher disease type 1 management algorithms and clinical decision making.
Collapse
Affiliation(s)
- Juliette Berger
- Hématologie Biologique, CHU Clermont-Ferrand, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France
- Université Clermont Auvergne, Equipe d'Accueil 7453 CHELTER, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France
- CHU Clermont-Ferrand, CHU Estaing, CRB Auvergne, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France
| | - Marie Vigan
- INSERM and University Paris Diderot, IAME, UMR 1137, Paris, France
- AP-HP, Department of Epidemiology, Biostatistic and Clinical Research, Bichat Hospital, 75018, Paris, France
| | - Bruno Pereira
- CHU Clermont-Ferrand, DRCI, CHU Montpied, 58 rue Montalembert, 63003, Clermont-Ferrand Cedex 1, France
| | - Thu Thuy Nguyen
- INSERM and University Paris Diderot, IAME, UMR 1137, Paris, France
| | - Roseline Froissart
- Hospices Civils de Lyon, Centre de Biologie et de Pathologie Est, Unité des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Service de Biochimie et Biologie Moléculaire Grand Est, 69677, Bron, France
| | - Nadia Belmatoug
- Médecine Interne, AP-HP, Hôpital Beaujon, 100 boulevard Général Leclerc, 92110, Clichy, France
| | - Florence Dalbiès
- Hématologie, CHRU Brest site Hôpital Morvan, 5 avenue Maréchal Foch, 29200, Brest, France
| | - Agathe Masseau
- Médecine Interne, CHU de Nantes, Hôtel-Dieu, 44093, Nantes, France
| | - Christian Rose
- Onco-Hématologie, Hôpital Saint-Vincent de Paul, boulevard de Belfort, 59000, Lille, France
| | - Christine Serratrice
- Hôpitaux Universitaires de Genève, Département de Médecine Interne, Hôpital des Trois-Chêne, Chemin du Pont-Bochet 3, Thônex, 1226, Geneva, Switzerland
| | - Yves-Marie Pers
- Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, 371 avenue du Doyen-Gaston-Giraud, 34295, Montpellier, France
| | - Ivan Bertchansky
- INSERM U1183, Saint-Eloi University Hospital, Montpellier, France
| | - Fabrice Camou
- Service de Médecine Interne et Maladies Infectieuses, CHU Bordeaux, Groupe Hospitalier Sud, avenue Magellan, 33604, Pessac Cedex, France
| | - Monia Bengherbia
- Médecine Interne, AP-HP, Hôpital Beaujon, 100 boulevard Général Leclerc, 92110, Clichy, France
| | - Céline Bourgne
- Hématologie Biologique, CHU Clermont-Ferrand, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France
- Université Clermont Auvergne, Equipe d'Accueil 7453 CHELTER, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France
| | - Catherine Caillaud
- INSERM U1151, Institut Necker Enfants Malades, Université Paris Descartes, Paris, France
- AP-HP, Hôpital Universitaire Necker Enfants Malades, Laboratoire de Biochimie, Métabolomique et Protéomique, 149 rue de Sèvres, 75005, Paris, France
| | - Magali Pettazzoni
- Hospices Civils de Lyon, Centre de Biologie et de Pathologie Est, Unité des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Service de Biochimie et Biologie Moléculaire Grand Est, 69677, Bron, France
| | - Amina Berrahal
- Hématologie Biologique, CHU Clermont-Ferrand, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France
| | - Jérôme Stirnemann
- Département de Médecine Interne, Hôpitaux Universitaires de Genève, Gabrielle Perret Gentil 4, 1211, Geneva, Switzerland
| | - France Mentré
- INSERM and University Paris Diderot, IAME, UMR 1137, Paris, France
- AP-HP, Department of Epidemiology, Biostatistic and Clinical Research, Bichat Hospital, 75018, Paris, France
| | - Marc G Berger
- Hématologie Biologique, CHU Clermont-Ferrand, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
- Université Clermont Auvergne, Equipe d'Accueil 7453 CHELTER, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
- CHU Clermont-Ferrand, CHU Estaing, CRB Auvergne, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
| |
Collapse
|
4
|
Bertchansky I, Chaze I, Donnadieu-Rigole H. Foie et déficit immunitaire. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Bertchansky I, Chaze I, Perney P, Donnadieu-Rigole H. Périartérite noueuse et hépatite virale C. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Bertchansky I, Amouroux C, Rento A, Segalas F, Rullier P, Konate AP, Blanc F, Donnadieu-Rigole H. Hépatite virale E et syndrome de Parsonage-Turner. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|